GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide 1) are incretin hormones with therapeutic potential on patients with T2DM, since they can increase the insulin release and decrease the glycogen release [7]. This evidence concerns the gene GIP and type 2 diabetes mellitus.